Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
IDEXX LaboratoriesHAM:IX1 -2.82%96 Equity-to-Asset is 0.47 as of Jun. 2026, which is 104% above its 10-year median of 0.23. GuruFocus rates HAM:IX1 with a GF Score™ of 96/100 and a GF Value™ of €544.63 (Modestly Undervalued). Among 211 Medical Diagnostics & Research companies, IDEXX Laboratories ranks worse than 65.88% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. IDEXX Laboratories's Total Stockholders Equity for the quarter that ended in Jun. 2026 was €1,400 Mil. IDEXX Laboratories's Total Assets for the quarter that ended in Jun. 2026 was €2,988 Mil.
Therefore, IDEXX Laboratories's Equity to Asset Ratio for the quarter that ended in Jun. 2026 was 0.47.
The historical rank and industry rank for IDEXX Laboratories's Equity-to-Asset or its related term are showing as below:
HAM:IX1'
s Equity-to-Asset Range Over the Past 10 Years
Min: -0.07 Med: 0.23 Max: 0.48
Current: 0.47
During the past 13 years, the highest Equity to Asset Ratio of IDEXX Laboratories was 0.48. The lowest was -0.07. And the median was 0.23.
HAM:IX1's Equity-to-Asset is ranked worse than 65.88% of 211
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.59
vs HAM:IX1: 0.47
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
IDEXX Laboratories Equity-to-Asset Related Terms
IDEXX Laboratories Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for IDEXX Laboratories's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HAM:IX1 vs A, NTRA, WAT: Equity-to-Asset Comparison
For the Diagnostics & Research subindustry, IDEXX Laboratories's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
IDEXX Laboratories Equity-to-Asset vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, IDEXX Laboratories's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where IDEXX Laboratories's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
IDEXX Laboratories's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IDEXX Laboratories (HAM:IX1) has a Equity-to-Asset of 0.47 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on IDEXX Laboratories and its competitors. This is 104% above median its historical median of 0.23. According to the industry distribution chart, IDEXX Laboratories ranks #139 out of 211 companies in the Medical Diagnostics & Research industry, placing it in the top 65.9%.
Is IDEXX Laboratories' Equity-to-Asset too high?
IDEXX Laboratories' current Equity-to-Asset of 0.47 is 104% above median its 10-year median of 0.23. The Medical Diagnostics & Research industry median Equity-to-Asset is 0.59. IDEXX Laboratories' value of 0.47 is 20.3% below this industry median. Based on the distribution chart, IDEXX Laboratories ranks #139 out of 211 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, IDEXX Laboratories has a GF Score™ of 96/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does IDEXX Laboratories' Equity-to-Asset compare to A and NTRA?
According to the Medical Diagnostics & Research industry distribution chart, IDEXX Laboratories ranks #139 out of 211 companies for Equity-to-Asset. This places IDEXX Laboratories in the lower half of its industry. The industry median Equity-to-Asset is 0.59. IDEXX Laboratories' value of 0.47 is 20.3% below this benchmark. While the company's 10-year median is 0.23 vs. the industry median of 0.59, IDEXX Laboratories has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Medical Diagnostics & Research company?
The median Equity-to-Asset among Medical Diagnostics & Research companies is 0.59, based on 211 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. IDEXX Laboratories's current Equity-to-Asset of 0.47 is 20.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on IDEXX Laboratories and its competitors. For the Medical Diagnostics & Research industry, the median Equity-to-Asset is 0.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. IDEXX Laboratories's current Equity-to-Asset is 0.47, which is 104% above median its own 10-year median of 0.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IDEXX Laboratories stock overvalued right now?
Based on GuruFocus' analysis, IDEXX Laboratories (HAM:IX1) is currently considered Modestly Undervalued. The stock's GF Value™ is €544.63, compared to a current price of €489.00 — trading 10.2% below its estimated fair value. The current Equity-to-Asset is 0.47, which is 104% above median its 10-year median of 0.23 and 20.3% below the Medical Diagnostics & Research industry median of 0.59. IDEXX Laboratories' overall GF Score™ is 96/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For IDEXX Laboratories (HAM:IX1), the current Equity-to-Asset is 0.47 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is IDEXX Laboratories (HAM:IX1) Overvalued in 2026?
Based on GuruFocus' analysis, IDEXX Laboratories stock appears to be undervalued.
The current stock price of €489.00 is trading 10.2% below its estimated GF Value™ of €544.63.
GuruFocus considers IDEXX Laboratories to be Modestly Undervalued.
Key valuation signals for HAM:IX1:
Equity-to-Asset: 0.47 (104% above median its 10-year median of 0.23)
GF Value™: €544.63 vs. price of €489.00 (10.2% below fair value)
Industry Position: 20.3% below the Medical Diagnostics & Research median (#139 of 211)
No single metric tells the full story. See the HAM:IX1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx derives roughly 35% of its revenue from outside the United States.
96GF Score
Get the complete analysis for HAM:IX1
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:IX1 has been successfully added to your 
